It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Myriad Genetics Inc (MYGN) Com Stk USD0.01

Sell:$27.34 Buy:$27.39 Change: $0.31 (1.15%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Change: $0.31 (1.15%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Change: $0.31 (1.15%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Contact details

320 S Wakara Way
United States
+1 (801) 5843600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.11 billion
Shares in issue:
77.05 million
United States
US dollar

Key personnel

  • S. Louise Phanstiel
    Independent Chairman of the Board
  • Paul Diaz
    President, Chief Executive Officer, Director
  • R. Bryan Riggsbee
    Chief Financial Officer, Executive Vice President, Treasurer
  • Nicole Lambert
    President of Myriad Womens Health, Oncology, and International
  • Mark Verratti
    President of Myriad Neuroscience and Myriad Autoimmune
  • Faith Zaslavsky
    President of Myriad Oncology
  • Benjamin Jackson
    Executive Vice President, General Counsel, Secretary
  • Jayne Hart
    Executive Vice President - Human Resources
  • Paul Parkinson
    Executive Vice President for Reimbursement Strategy
  • Jeff Borcherding
    Senior Vice President, Chief Marketing Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.